Vitura Health Limited

ACN 629 071 594

ASX Appendix 4E

Results for announcement to the Market for the year ended 30 June 2026

1. The reporting period covers the year ended 30 June 2026.
   The previous reporting period covers the year ended 30 June 2025.

2. Results for announcement to the Market

		30 June 2026 $	30 June 2025 $	Increase/ (decrease) $	Increase %
2.1	Total revenues from ordinary activities	131,158,015	124,036,970	7,121,045	5.7%
2.2	The profit/(loss) from ordinary activities after tax attributable to Members	(4,392,015)	3,324,321	(7,716,336)	N/A
2.3	The net profit/(loss) attributable to Members	(4,392,015)	3,324,321	(7,716,336)	N/A
2.4	On 22 August 2025, the Directors resolved to pay a dividend of 0.2 cents per ordinary share franked as to 100% in respect of the year ended 30 June 2025. The Record Date for the dividend was 8 September 2025, and the total amount of the dividend was $1,324,510. Of this amount, $1,293,541 was paid in cash, with the remaining $30,969 being satisfied through the allotment of 486,981 shares under the Company's Dividend Reinvestment Plan, which occurred on 30 September 2025. The Directors of the Company have resolved not to declare a dividend in respect of the year ended 30 June 2026.				
2.5	Not applicable.				

2.6 Current period commentary

Statement of Comprehensive Income

During the year ended 30 June 2026, the Company generated a consolidated loss after income tax of $4,406,176 (2025: profit $3,061,855). This result reflected a continued decline in the average selling price of products sold through the Canview platform and industry-wide gross margin pressures arising from increased competition. It also reflected increased amortisation of intangible assets ($970,735) and interest expense on bank debt ($89,192).

IT related costs decreased by $1,368,099, reflecting higher development costs incurred in the prior year in relation to the Canview platform. The Company continued to enhance the platform during the current year to support growth in subsequent financial years. Sales and marketing costs increased $692,854 as the Company expanded into new product and service verticals and B2B partnerships. Personnel expenses increased by 11% year-on-year, due to redundancy and other related costs.

Revenues generated during the year ended 30 June 2026 totalled $131,158,015, representing an increase of ~6% over the figure for the prior corresponding period of $124,036,970. The increased was comprised of:

- a 4% increase in product sale and distribution revenue to $100,371,819 (2025: $96,368,426), and;
- an 11% increase in medical consultation and service fees to $30,786,196 (2025: $27,668,544).

Medical consultation and service fee revenue included a full year of revenue from the acquisition of Candor Medical which was acquired in February 2025.

Revenue from the sale and distribution of products through Canview increased 4% compared with the prior corresponding period. Units sold for medicinal cannabis increased 10% and nicotine vaping products (NVP) increased 119%.

During FY2026, the Australian medicinal cannabis industry continued to experience average selling price compression across many products (also referred to as SKUs (stock keeping units)) due to increased competition. The average selling price fell 8% across during the year. To support sales amid increasing competition, the Company continued to offer pricing discounts and rebates. This had a corresponding impact on the average gross margin realised from those sales.

Revenues from the provision of clinical consulting and other services increased by $3,117,652, or 11%, from the prior corresponding period. The increase reflected a full year of revenue from Candor Medical and an higher telehealth consultation volumes among several of Doctors on Demand's (DoD) larger B2B customers. Average monthly consultations increased 20% compared with FY2025.

Revenues from DoD's B2B customers increased $4,617,553, or 24%, from the prior corresponding period. The Company expects to broaden its patient base in FY2027 as additional customers are sought to access DoD's services.

The average gross margin achieved across the Group from the sale of products during the year ended 30 June 2026 was 19%, approximately 5 percentage points below the prior corresponding period. As noted above, the medicinal cannabis industry continues to experience market-wide compression. The average selling price of SKUs offered on Canview fell from $105 to $97 during FY2026, placing pressure on gross margins. These pressures were party offset by by the Company's clinic operations which achieved a higher average gross margin of approximately 30%. With Candor fully integrated into the Group, the Specialty Clinics business unit continues to grow. The Company expects this growth to continue to offset the margin pressure experienced in medicinal cannabis sales in future years.

Expenses incurred during the year under review totalled $31,830,568 (2025: $29,760,242), being an increase of $2,070,326, or 7%, from the prior corresponding period. The increase was driven by a 36% increase in sales and marketing costs and an 11% increase in personnel expenses. These costs supported the expansion of doctor and clinic networks, entry into new product and service verticals, and expanding B2B partnerships. IT costs decreased 40%, reflecting lower Canview platform maintenance requirements than in the prior corresponding period and continued capitalisation of development costs for integrated platform improvements expected to deliver ongoing benefits in future years.

Statement of Financial Position

During the year ended 30 June 2026, the Group's cash and cash equivalents decreased by $2,229,891, or 29%, to $5,349,206 (2025: $7,579,097). The decrease primarily reflected:

- payment of a dividend of $1,293,541 on 30 September 2025; and
- a $526,240 increase in bank and merchant charges.

Trade and other receivables increased by $3,948,096, or 37%, compared with the prior year, largely due to a successful end-of-financial-year sale undertaken in June 2026. Other receivables included:

- $500,060 (2025: $420,180) expected payroll tax refunds relating to doctor contractors who provide services to the Group's clinics; and
- $1,063,644 in supplier rebates.

Further amounts of $2,173,697 (2025: $1,242,391) and $1,951,028 (2025: $nil) relate to loans that the Company has provided to the Flora and Cortexa joint ventures, respectively, to expand these businesses which are recorded as non-current other assets in the balance sheet at 30 June 2026.

Inventories held by the Group at balance date were $4,133,596, down $1,844,211, or 31%, compared with the prior corresponding period due to a decrease in deposits paid on products in production. While the total number of discrete SKUs sold through the Canview platform now exceeds 1,300, a larger proportion are held by the Company on a consignment basis and are therefore not included as inventories. The provision for obsolete stock at 30 June 2026 increased by $1,101,026, or 1,380% due primarily to one supplier accounting for $892,285 of the total, with the remaining provision relating to several slow-moving SKUs.

Intangible assets decreased by $1,433,558, or approximately 4%, compared with the prior corresponding to $38,809,580 (2025: $40,243,138). The net reduction comprised capitalised IT costs of $2,325,325, offset by amortisation of $2,126,485 and impairment of the goodwill balances relating to Doctors on Demand Pty Ltd and Cannadoc health Pty Ltd totalling $1,632,499 (refer Note 16). The benefit of the capitalised development costs is expected to be realised in the 2027 financial year and beyond, following completion and deployment of the respective projects.

Total liabilities of the Group increased by $5,909,665, or 21%, compared with the previous period. This increase is primarily related to the increase in the trade facility the Company has with ANZ Bank. As disclosed in Notes 20 and 23, the total ANZ debt has been classified as a current liability as at 30 June 2026. Several leases related to premises occupied by the Group are under review for renewal, significantly reducing both the right-of-use assets and corresponding lease liabilities pursuant to AASB 16 *Leases*.

Statement of Cash Flows

During the year ended 30 June 2026, cash receipts from customers (including GST) were $128,437,118, a decrease of $6,346,758, or 5%, compared to the previous corresponding period. Net cash flows from operations decreased $2,758,702. This was primarily reflected a successful end of financial year sales campaign which increased revenues but resulted in associated cash receipts being collected in early FY2027. This was partially offset by a $681,366 decrease in tax payments.

Interest paid during the year also increased by $89,192, reflecting higher borrowings from ANZ Bank and an increase of approximately 0.5% per annum in the average interest rate,compared to the prior year.

Cash outflows used in investing activities during the year were $3,740,583, representing a decrease of $10,127,114, due primarily to the $6,250,000 acquisition of Doctors on Demand in the prior year, lower acquisition costs of $1,814,663 for Livelihood Health Pty Ltd (the owner of Candor Medical), and reduced development work undertaken on the Canview and Doctors on Demand platforms.

Net cashflows from financing activities decreased by $5,829,513 compared with the prior year to a net inflow of $1,601,717 in FY2026. This is due to a net drawdown of debt from ANZ Bank of $1,383,133 and the issue of ordinary shares in the prior year to raise $5,171,196, most of which was used to fund the acquisition of Livelihood Health Pty Ltd, as described above.

3. The audited Consolidated Statement of Comprehensive Income for the Group covering the Reporting Period and the Previous Period is provided on page 39 of the Company's 2026 Financial Report (the "Report"). Notes to the Statement are provided from page 43 to page 82 of the Report.

4. The audited Consolidated Statement of Financial Position for the Group covering the Reporting Period and the Previous Period is provided on page 40 of the Report. Notes to the Statement are provided from page 43 to page 82 of the Report.

5. The audited Consolidated Statement of Cash Flows for the Group covering the Reporting Period and the Previous Period is provided on page 42 of the Report. Notes to the Statement are provided from page 43 to page 82 of the Report and Note 30 on page 68 of the Report, in particular.

6. The audited Consolidated Statement of Changes in Equity covering the Reporting Period and the Previous Period is provided on page 41 of the Report. Notes to the Statement are provided from page 43 to page 82 of the Report and a statement of retained earnings covering the same periods is included as Note 27 on page 66 of the Report.

7. On 22 August 2025, the Directors resolved to pay a dividend of 0.2 cents per ordinary share franked as to 100% in respect of the year ended 30 June 2025. The Record Date for the dividend was 8 September 2025, and the total amount of the dividend was $1,324,510. Of this amount, $1,293,541 was paid in cash, with the remaining $30,969 being satisfied through the allotment of 486,981 shares under the Company's Dividend Reinvestment Plan, which occurred on 30 September 2025. The Directors of the Company have resolved not to declare a dividend in respect of the year ended 30 June 2026.

8. Not applicable.

9. Net tangible assets per ordinary share as at 30 June 2026 were 0.62 cents.

   Net tangible assets per ordinary share as at 30 June 2025 were 1.21 cents.

10. During the year ended 30 June 2026, the Company gained or lost control over the following entities:

Name of entity	Cortexa Pty Ltd
Control gained or lost	Lost
Type of transaction	Loss of effective control resulted in the deconsolidation of Cortexa Pty Ltd
Date of change	1 July 2025
Financial impact	The deconsolidation of Cortexa from 1 July 2025 resulted in positive net asset impact of $1,034,035

11. As at 30 June 2026, the Company held a 50 percent equity interest in an incorporated joint venture called Cortexa Pty Ltd which operates in the psychedelics industry. A net loss of $213,684 (being 50% of the total Cortexa loss of $427,368) was incurred by the Company from this joint venture during the year ended 30 June 2026.

    Also, as at 30 June 2026, the Company held a 42.5 percent equity interest in an incorporated joint venture called Flora Holdings Pty Ltd which operates several medicinal cannabis clinic businesses. A net loss of $295,688 was incurred by the Company from this joint venture during the year ended 30 June 2026.

12. Apart from the information contained in the Report and elsewhere in this Appendix 4E, there is no other significant information needed by an investor to make an informed assessment of the Company's financial performance and financial position as at the Reporting Date.

13. The audited consolidated financial statements that are contained in the Report have been prepared in accordance with International Financial Reporting Standards.

14. A commentary on the Company's results for the Reporting Period has been provided in the Financial Analysis section and other sections contained in the Directors' Report which forms part of the Report. Details pertaining to the Group's operating segments are contained in Note 35 on pages 73 to 74 of the Report.

15. The consolidated financial statements for the Group covering the Reporting Period and the Previous Period have been audited by the Company's auditor, Pilot Partners.

16. Not applicable.

17. The Financial Report for the year ended 30 June 2026 was audited by the Company's auditor, Pilot Partners. The audit report provided by Pilot Partners does not contain any modified opinion or emphasis of matter.

Signed on behalf of Vitura Health Limited

ROBERT IERVASI
Chair

Dated this 25th day of August, 2026